埃皮米丁A通过负调节TRAF6表达来抑制PI3K/AKT/NF-κB信号轴和骨质细胞分化
Jun Li1, Jia J Wei2, Cen H Wu3
1Department of Spine Surgery, Changzhou TCM Hospital Affiliated to Nanjing University of Chinese Medicine, Changzhou, 213000, People's Republic of China. lijun331188@163.com.
Molecular medicine (Cambridge, Mass.)
|August 16, 2024
概括
埃皮梅丁A (EA) 通过抑制骨质细胞形成和骨再吸收,有效治疗骨质疏松症. 这项研究揭示了EA的机制涉及抑制TRAF6/PI3K/AKT/NF-κB通路,提供了一个潜在的治疗策略.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 骨生物学和骨质疏松症研究研究
背景情况:
- 埃皮米丁A (EA) 显示出抑制骨质结晶发生和骨再吸收的潜力.
- 在EA对骨代谢的影响背后的精确机制需要进一步阐明.
研究的目的:
- 为了研究Epimedin A (EA) 对骨质细胞形成和骨再吸收的影响.
- 探索涉及EA对骨代谢作用的信号通路.
主要方法:
- 使用了卵巢切除的老鼠模型和体外RAW264.7细胞培养.
- 评估了骨矿物质密度,生物力学特性和骨质细胞分化标志物.
- 西方斑块和定量PCR分析了关键蛋白质和基因表达,重点关注TRAF6/PI3K/AKT/NF-κB通路.
主要成果:
- 在经过卵巢切除的老鼠中,EA治疗剂量取决于改善了骨矿物质密度和微观架构.
- 在体外,EA通过抑制TRAF6/PI3K/AKT/NF-κB通路来抑制骨质细胞分化.
- 过度表达TRAF6基因逆转了EA对骨质细胞分化的抑制作用.
结论:
- 埃皮米丁A (EA) 通过抑制TRAF6/PI3K/AKT/NF-κB信号轴来负面调节骨质细胞形成.
- 经过卵巢切除,EA提出了一种有前途的治疗策略,用于改善卵巢切除引起的骨质疏松症.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Regulation of Angiogenesis and Blood Supply
2.5K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.5K
MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


